{"id":"abacavir-lamivudine","safety":{"commonSideEffects":[{"rate":"5-8","effect":"Hypersensitivity reaction (abacavir)"},{"rate":"2-5","effect":"Headache"},{"rate":"2-5","effect":"Nausea"},{"rate":"2-5","effect":"Diarrhea"},{"rate":"2-5","effect":"Fatigue"},{"rate":"1-3","effect":"Insomnia"},{"rate":"<1","effect":"Lactic acidosis (rare)"}]},"_chembl":{"chemblId":"CHEMBL4303288","moleculeType":"Small molecule","molecularWeight":"670.76"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Both drugs are nucleoside analogs that compete with natural nucleotides for incorporation into the growing DNA chain during reverse transcription. Once incorporated, they cause chain termination, effectively halting HIV replication. This combination is used as part of antiretroviral therapy to suppress viral load in HIV-infected patients.","oneSentence":"Abacavir and lamivudine are nucleoside reverse transcriptase inhibitors (NRTIs) that block HIV reverse transcriptase, preventing viral replication by inhibiting conversion of viral RNA to DNA.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:41:55.258Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection (as part of combination antiretroviral therapy)"}]},"trialDetails":[{"nctId":"NCT02016924","phase":"PHASE2, PHASE3","title":"Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2014-01-16","conditions":"Acquired Immune Deficiency Syndrome (AIDS), HIV Infections","enrollment":133},{"nctId":"NCT02938520","phase":"PHASE3","title":"Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2016-10-27","conditions":"HIV Infections","enrollment":631},{"nctId":"NCT06337032","phase":"PHASE4","title":"A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-08-27","conditions":"HIV-1-infection","enrollment":350},{"nctId":"NCT07001319","phase":"PHASE1","title":"Study of GS-3242 in Participants With HIV-1; Substudy-05","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2025-05-29","conditions":"HIV-1-infection","enrollment":30},{"nctId":"NCT03016533","phase":"PHASE3","title":"Dolutegravir Study in HIV-1 Participants Completing IMPAACT Studies P1093 and P2019","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2017-06-06","conditions":"HIV Infections","enrollment":100},{"nctId":"NCT06630299","phase":"PHASE3","title":"Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-10-08","conditions":"HIV-1-Infection","enrollment":600},{"nctId":"NCT07115368","phase":"PHASE1","title":"Study of GS-1219 in Participants With HIV-1","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2025-08-11","conditions":"HIV-1-infection","enrollment":4},{"nctId":"NCT05502341","phase":"PHASE2, PHASE3","title":"Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2022-08-16","conditions":"HIV-1-infection","enrollment":689},{"nctId":"NCT03360682","phase":"PHASE4","title":"Clinical Trial to Evaluate the Efficacy, Pharmacokinetics (PK) Interactions and Safety of Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in HIV-1-Infected Solid Organ Transplant Patients","status":"COMPLETED","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2018-04-13","conditions":"HIV-1-infection, Solid Organ Transplant","enrollment":19},{"nctId":"NCT02363452","phase":"PHASE2","title":"Reverse Transcriptase Inhibitors in AGS","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2015-09-10","conditions":"Aicardi-Goutières Syndrome (AGS)","enrollment":11},{"nctId":"NCT07138144","phase":"PHASE4","title":"Efficacy, Safety, and ToLerability of Switching to A Two-Drug Regimen With DTG/3TC Compared to Maintaining A Three-Drug REgimen With BIC/FTC/TAF or DTG/3TC/ABC in ViroLogically SupprEssed PeopLe Living With HIV After 24 and 48 Weeks of Follow-Up","status":"RECRUITING","sponsor":"José Antonio Mata Marín","startDate":"2025-07-12","conditions":"HIV Infections","enrollment":156},{"nctId":"NCT02470650","phase":"PHASE4","title":"Cost-effectiveness of Different Antiretroviral Treatment in Patients HIV Naive","status":"WITHDRAWN","sponsor":"Juan A. Arnaiz","startDate":"2015-06","conditions":"Patient Compliance, Antiretroviral Therapy Intolerance","enrollment":""},{"nctId":"NCT07080138","phase":"","title":"Research on the Psychological Status of Patients With HIV-1 Infection","status":"NOT_YET_RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2025-08-01","conditions":"HIV-1-infection, Anxiety Depression","enrollment":500},{"nctId":"NCT05729568","phase":"PHASE2","title":"A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2023-05-15","conditions":"HIV Infection","enrollment":83},{"nctId":"NCT05193994","phase":"PHASE3","title":"Triumeq in Amyotrophic Lateral Sclerosis","status":"TERMINATED","sponsor":"Macquarie University, Australia","startDate":"2022-02-24","conditions":"Amyotrophic Lateral Sclerosis","enrollment":419},{"nctId":"NCT06428045","phase":"PHASE1","title":"STARLITE for Unresectable High-Grade Gliomas","status":"RECRUITING","sponsor":"University of Miami","startDate":"2025-04-15","conditions":"High Grade Glioma","enrollment":24},{"nctId":"NCT06658977","phase":"PHASE3","title":"RolloverTreatment With Triumeq for People With ALS Following the Lighthouse II Trial","status":"TERMINATED","sponsor":"Macquarie University, Australia","startDate":"2024-11-15","conditions":"Amyotrophic Lateral Sclerosis, ALS","enrollment":12},{"nctId":"NCT00796263","phase":"PHASE3","title":"Antiretroviral Therapy for Acute and Chronic HIV Infection","status":"RECRUITING","sponsor":"SEARCH Research Foundation","startDate":"2009-05-13","conditions":"Acute HIV Infection, Chronic HIV Infection","enrollment":900},{"nctId":"NCT05585307","phase":"PHASE1","title":"Study of Novel Antiretrovirals in Participants With HIV-1","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2022-10-26","conditions":"HIV-1-infection","enrollment":49},{"nctId":"NCT04012931","phase":"PHASE2","title":"A Study of Switching to RPV Plus Other ARVs in HIV-1-infected Children (Aged 2 to <12 Years) Who Are Virologically Suppressed","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2019-07-18","conditions":"HIV","enrollment":26},{"nctId":"NCT02275780","phase":"PHASE3","title":"Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1) (MK-1439-018)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-12-01","conditions":"HIV-1","enrollment":769},{"nctId":"NCT06602622","phase":"PHASE4","title":"Change in Body Weight and BMI in PWH with DOR/3TC/TDF Compared with INSTI","status":"RECRUITING","sponsor":"Instituto Mexicano del Seguro Social","startDate":"2024-08-14","conditions":"HIV, HIV Associate Weight Loss, HIV-1 Infection","enrollment":108},{"nctId":"NCT01059422","phase":"PHASE4","title":"Raltegravir + Lamivudine/Abacavir in HIV/Tuberculosis Co-Infected Patients","status":"COMPLETED","sponsor":"Central Institute of Epidemiology, Moscow, Russia","startDate":"2010-10","conditions":"HIV Infections, Tuberculosis","enrollment":10},{"nctId":"NCT04493216","phase":"PHASE2","title":"A Dose-Range Finding Clinical Trial Study in Human Immunodeficiency Virus (HIV-1) Infected Treatment-Naive Adults","status":"TERMINATED","sponsor":"ViiV Healthcare","startDate":"2020-11-18","conditions":"HIV Infections","enrollment":161},{"nctId":"NCT00799864","phase":"PHASE2","title":"A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 Years","status":"COMPLETED","sponsor":"Janssen Sciences Ireland UC","startDate":"2011-01","conditions":"HIV-1","enrollment":54},{"nctId":"NCT02120352","phase":"PHASE2","title":"A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2014-04-28","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":309},{"nctId":"NCT04904406","phase":"PHASE4","title":"Changes in Weight, Body Composition and Cardiac Risk After Discontinuing Abacavir Treatment in HIV-infected Individuals","status":"COMPLETED","sponsor":"Thomas Benfield","startDate":"2020-10-22","conditions":"Hiv, HIV Infections, HIV Cardiomyopathy","enrollment":81},{"nctId":"NCT04731103","phase":"PHASE2","title":"Inhibition of Reverse Transcription in Aicardi-Goutières Syndrome","status":"COMPLETED","sponsor":"University of Edinburgh","startDate":"2022-08-24","conditions":"Aicardi-Goutières Syndrome","enrollment":13},{"nctId":"NCT02659761","phase":"PHASE4","title":"Triumeq As an Integrase Single Tablet Regimen in People With HIV Who Inject Drugs","status":"TERMINATED","sponsor":"University College Dublin","startDate":"2016-11","conditions":"Human Immunodeficiency Virus","enrollment":33},{"nctId":"NCT06356740","phase":"PHASE2","title":"Efficacy and Tolerance of Abacavir/Lamivudine Treatment in Patients With Systemic Lupus Erythematosus","status":"NOT_YET_RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2024-09-01","conditions":"Systemic Lupus Erythematosus","enrollment":70},{"nctId":"NCT01910402","phase":"PHASE3","title":"A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2013-08-22","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":499},{"nctId":"NCT02708342","phase":"","title":"Observational, Retrospective Analysis in HIV-1 Infected Patients. (ORASWIRAL)","status":"COMPLETED","sponsor":"IRCCS San Raffaele","startDate":"2016-04","conditions":"HIV","enrollment":100},{"nctId":"NCT01605084","phase":"PHASE3","title":"Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone","status":"WITHDRAWN","sponsor":"Bristol-Myers Squibb","startDate":"2012-06-30","conditions":"HIV","enrollment":""},{"nctId":"NCT02486133","phase":"PHASE3","title":"Dual Therapy With Boosted Darunavir + Dolutegravir","status":"COMPLETED","sponsor":"Technical University of Munich","startDate":"2015-07","conditions":"HIV-Infection","enrollment":269},{"nctId":"NCT03178084","phase":"PHASE3","title":"Effects of Maraviroc vs. Efavirenz on CD4/CD8 Ratio","status":"COMPLETED","sponsor":"Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal","startDate":"2014-10-15","conditions":"HIV/AIDS","enrollment":721},{"nctId":"NCT04340388","phase":"PHASE4","title":"Contribution of Dolutegravir to Obesity and Cardiovascular Disease","status":"COMPLETED","sponsor":"Augusta University","startDate":"2020-09-17","conditions":"HIV-1-infection, Antiviral Drug Adverse Reaction, Vascular Diseases","enrollment":10},{"nctId":"NCT03760458","phase":"PHASE1, PHASE2","title":"The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-09-09","conditions":"HIV Infections","enrollment":57},{"nctId":"NCT04827134","phase":"PHASE1","title":"A Food-effect Study of the Pediatric Dispersible Tablet Formulations of TRIUMEQ® and DOVATO® in Healthy Adult Participants","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2021-05-07","conditions":"HIV Infections","enrollment":33},{"nctId":"NCT03656783","phase":"PHASE3","title":"Effects of Biktarvy on CFR in Stable HIV Patients","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2018-09-14","conditions":"HIV","enrollment":25},{"nctId":"NCT04301661","phase":"","title":"Cellular Pharmacology and Platelet Effects of Abacavir and Lamivudine Anabolites","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2020-03-06","conditions":"HIV-1-infection","enrollment":25},{"nctId":"NCT02924389","phase":"PHASE4","title":"Dolutegravir in Reservoirs","status":"TERMINATED","sponsor":"Emory University","startDate":"2016-09","conditions":"HIV","enrollment":22},{"nctId":"NCT02075593","phase":"PHASE3","title":"ING200336, Pharmacokinetic and Safety Study in Pregnant Women With Human Immuno Virus Infection","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2014-12-17","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections, Arthralgia","enrollment":4},{"nctId":"NCT05525156","phase":"PHASE2","title":"The Effect of Aspirin on HIV Disease Progression Among HIV- Infected Individuals Initiating Anti- Retroviral Therapy","status":"SUSPENDED","sponsor":"Muhimbili University of Health and Allied Sciences","startDate":"2020-03-02","conditions":"Hiv, Cardiovascular Diseases","enrollment":454},{"nctId":"NCT03685500","phase":"PHASE4","title":"A Clinical Trial to Evaluate the Reversibility of Abacavir/Lamivudine/Dolutegravir CNS-Related Neurotoxicity After Switching to Tenofovir/Alafenamide/Emtricitabine/Darunavir/Cobicistat (TAF/FTC/DRV/c)","status":"COMPLETED","sponsor":"Fundacion SEIMC-GESIDA","startDate":"2018-12-04","conditions":"HIV Infections","enrollment":78},{"nctId":"NCT05030025","phase":"EARLY_PHASE1","title":"Abacavir, Dolutegravir and Lamivudine Dispersible Tablets (60 mg/5 mg/30 mg)","status":"COMPLETED","sponsor":"Mylan Inc.","startDate":"2021-08-01","conditions":"HIV-1-infection","enrollment":43},{"nctId":"NCT02607930","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in Human Immunodeficiency Virus-1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-13","conditions":"HIV-1 Infection","enrollment":631},{"nctId":"NCT02384395","phase":"NA","title":"Safety and Efficacy of Fixed Dose Combination Dolutegravir/Abacavir/Lamivudine FDC Initiated During Acute HIV Infection","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2015-09","conditions":"HIV, Acute HIV Infection","enrollment":40},{"nctId":"NCT00039741","phase":"PHASE2, PHASE3","title":"Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2002-08","conditions":"HIV Infections","enrollment":266},{"nctId":"NCT00084149","phase":"PHASE2","title":"Cyclosporine A in Combination With Abacavir Sulfate, Lamivudine, and Zidovudine and Lopinavir/Ritonavir in HIV","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2004-02","conditions":"HIV Infections","enrollment":54},{"nctId":"NCT00000872","phase":"PHASE2","title":"Treatment With Combinations of Several Antiviral Drugs in Infants and Young Children With HIV Infection","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":55},{"nctId":"NCT00102960","phase":"PHASE3","title":"Anti-HIV Drugs for Treating Infants Who Acquired HIV Infection at Birth","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-07","conditions":"HIV Infections","enrollment":377},{"nctId":"NCT00270296","phase":"PHASE2","title":"Trizivir Vs. Kaletra and Combivir for the Prevention of Mother-to-Child Transmission of HIV","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-06","conditions":"HIV Infections","enrollment":730},{"nctId":"NCT00051090","phase":"NA","title":"Treatment of Hepatitis B Virus (HBV) Before Beginning Anti-HIV Drugs in Patients With Both HBV and HIV","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, Hepatitis B","enrollment":""},{"nctId":"NCT00086359","phase":"PHASE3","title":"Comparison of Anti-HIV Drug Combinations to Prevent Mother-to-Child Transmission of HIV","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2004-07","conditions":"HIV Infections","enrollment":19},{"nctId":"NCT00004855","phase":"NA","title":"Effects of Two Anti-HIV Drug Combinations on the Immune Systems of HIV-Infected Patients Who Have Never Received Anti-HIV Drugs","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":55},{"nctId":"NCT00102206","phase":"PHASE2","title":"A Comparison of Two Anti-HIV Drug Regimens for Youth Who Have Failed Prior Therapy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":6},{"nctId":"NCT00000940","phase":"PHASE2","title":"Five-Drug Anti-HIV Treatment Followed by Treatment Interruption in Patients Who Have Recently Been Infected With HIV","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"1999-05","conditions":"HIV Infections","enrollment":121},{"nctId":"NCT00000865","phase":"PHASE1","title":"The Safety and Effects of 1592U89 Used Alone or in Combination With Other Anti-HIV Drugs in HIV-Infected Infants and Children","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":32},{"nctId":"NCT00000885","phase":"PHASE2","title":"Treatment Success and Failure in HIV-Infected Subjects Receiving Indinavir in Combination With Nucleoside Analogs: A Rollover Study for ACTG 320","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":440},{"nctId":"NCT03631732","phase":"PHASE3","title":"Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-08-28","conditions":"HIV-1 Infection","enrollment":496},{"nctId":"NCT03447873","phase":"PHASE4","title":"Tripe Versus Dual Antiretroviral Therapy in HIV-infected Patients With Virological Suppression (Tridual)","status":"COMPLETED","sponsor":"Hospitales Universitarios Virgen del Rocío","startDate":"2017-06-01","conditions":"HIV Infections","enrollment":153},{"nctId":"NCT03602690","phase":"PHASE2","title":"Evaluation of Third-line cART Regimen in Cambodia (3DICAM)","status":"UNKNOWN","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2018-10-04","conditions":"HIV/AIDS","enrollment":54},{"nctId":"NCT01352715","phase":"PHASE3","title":"Study of Options for Second-Line Effective Combination Therapy (SELECT)","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2012-03-13","conditions":"HIV-1 Infection","enrollment":515},{"nctId":"NCT02603107","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-20","conditions":"HIV-1 Infection","enrollment":578},{"nctId":"NCT02569346","phase":"PHASE1","title":"Bioequivalence Study of CRushed TriUMeq With or Without Drip Feed Compared to the Whole Tablet","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2016-03","conditions":"HIV","enrollment":22},{"nctId":"NCT02603120","phase":"PHASE3","title":"Safety and Efficacy of Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-11","conditions":"HIV-1 Infection","enrollment":567},{"nctId":"NCT04600687","phase":"NA","title":"B/F/TAF Ease of Swallowability Trial","status":"COMPLETED","sponsor":"Henry Ford Health System","startDate":"2018-11-06","conditions":"HIV Infections","enrollment":50},{"nctId":"NCT03284645","phase":"","title":"Viral and Antiretroviral Dynamics in HIV-1 Mother-to-Child Transmission Fluids","status":"COMPLETED","sponsor":"Obafemi Awolowo University","startDate":"2017-12-22","conditions":"Human Immunodeficiency Virus Infection","enrollment":194},{"nctId":"NCT00046176","phase":"PHASE3","title":"A HIV Study Of A Fixed-Dose Combination Tablet In Antiretroviral Experienced Patients","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2002-08-26","conditions":"Infection, Human Immunodeficiency Virus I, HIV Infection","enrollment":240},{"nctId":"NCT00044577","phase":"PHASE3","title":"New Tablet Containing Two FDA Approved Anti-HIV Drugs For Antiretroviral Therapy Experienced HIV-1 Infected Subjects","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2002-07-16","conditions":"Infection, Human Immunodeficiency Virus I, HIV Infection","enrollment":166},{"nctId":"NCT02995824","phase":"","title":"Effectiveness of Raltegravir-Based Antiretroviral Therapy in HIV-HCV Coinfected Liver Transplant Recipients","status":"COMPLETED","sponsor":"Hospital Clinic of Barcelona","startDate":"2002-01","conditions":"Liver Transplantation, HIV Infections, Antiretroviral Therapy","enrollment":271},{"nctId":"NCT03067285","phase":"PHASE4","title":"A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study","status":"COMPLETED","sponsor":"Fundacion SEIMC-GESIDA","startDate":"2017-09-08","conditions":"HIV Infections","enrollment":39},{"nctId":"NCT04155554","phase":"PHASE3","title":"Neurological Monitoring in Patients Switching From Dolutegravir Based Regimen to Bictegravir Based Regimen","status":"UNKNOWN","sponsor":"Azienda Ospedaliera Universitaria Senese","startDate":"2020-01-29","conditions":"HIV-1-infection","enrollment":100},{"nctId":"NCT01641809","phase":"PHASE2","title":"Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2012-08-06","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":244},{"nctId":"NCT01367236","phase":"PHASE4","title":"Changes in Cerebral Function in Treatment Naive HIV-1 Infected Subjects Commencing Either Boosted Atazanavir With Truvada or Boosted Darunavir With Maraviroc and Kivexa","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2013-01","conditions":"HIV, Impaired Cognition","enrollment":60},{"nctId":"NCT03224338","phase":"PHASE2","title":"Dolutegravir Plus 2 NRTIs, in Treatment-Naïve HIV-2 Infected Subjects","status":"COMPLETED","sponsor":"Blueclinical, Ltd.","startDate":"2017-04-05","conditions":"HIV II Infection","enrollment":30},{"nctId":"NCT02868580","phase":"PHASE2","title":"Safety and Tolerability of Antiretroviral (Triumeq) in Patients With Amyotrophic Lateral Sclerosis (ALS).","status":"COMPLETED","sponsor":"Neuroscience Trials Australia","startDate":"2016-10","conditions":"Amyotrophic Lateral Sclerosis","enrollment":43},{"nctId":"NCT03836833","phase":"PHASE1, PHASE2","title":"Lopinavir/r/ Lamivudine/ Abacavir as an Easy to Use Paediatric Formulation","status":"UNKNOWN","sponsor":"Drugs for Neglected Diseases","startDate":"2019-06-04","conditions":"HIV","enrollment":50},{"nctId":"NCT01900106","phase":"PHASE3","title":"A Prospective, Open-label Trial of Two ABC/3TC Based Regimens in Late Presenter naïve Patients (CD4 <200 Cells/µL)","status":"COMPLETED","sponsor":"University of Modena and Reggio Emilia","startDate":"2013-11","conditions":"HIV Infection","enrollment":47},{"nctId":"NCT02342769","phase":"","title":"Prospective Non-Interventional Observational Study of Use of TRIUMEQ and Corresponding Monitoring Measures in Clinical Practice in Germany","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2015-02-19","conditions":"HIV Infections","enrollment":403},{"nctId":"NCT00978068","phase":"PHASE3","title":"HIV Protease Inhibitors for the Prevention of Malaria in Ugandan Children","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2009-09","conditions":"Malaria, HIV Infections","enrollment":176},{"nctId":"NCT02605954","phase":"PHASE3","title":"Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-18","conditions":"HIV-1 Infection","enrollment":275},{"nctId":"NCT02596334","phase":"PHASE3","title":"Study to Evaluate the Efficacy of MONotherapy of TiviCAY® Versus a Triple Therapy in HIV-1-infected Patients","status":"TERMINATED","sponsor":"Centre Hospitalier Régional d'Orléans","startDate":"2015-12-23","conditions":"HIV","enrollment":158},{"nctId":"NCT00449436","phase":"PHASE4","title":"Study To Evaluate Long Term Maintenance With TRIZIVIR After Boosted Protease Inhibitor (PI) Or Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) In HIV-1 Infected Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-01-10","conditions":"HIV Infections","enrollment":152},{"nctId":"NCT00118898","phase":"PHASE3","title":"Efavirenz or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir Disoproxil Fumarate or Abacavir/Lamivudine in HIV Infected Treatment-Naive Adults","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2005-09","conditions":"HIV Infections","enrollment":1864},{"nctId":"NCT01227824","phase":"PHASE3","title":"A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2010-10-19","conditions":"Infection, Human Immunodeficiency Virus I","enrollment":828},{"nctId":"NCT00427297","phase":"PHASE3","title":"Optimizing Pediatric HIV-1 Treatment in Infants With Prophylactic Exposure to Nevirapine, Nairobi, Kenya","status":"TERMINATED","sponsor":"University of Washington","startDate":"2007-09","conditions":"HIV Infections","enrollment":34},{"nctId":"NCT02337322","phase":"PHASE4","title":"Immune Recovery in Advanced , ARV-naïve, HIV-1-infected Individuals Taking Dolutegravir or Ritonavir-boosted Darunavir","status":"UNKNOWN","sponsor":"Juan A. Arnaiz","startDate":"2015-03-31","conditions":"Acquired Immune Deficiency Syndrome Virus","enrollment":104},{"nctId":"NCT01263015","phase":"PHASE3","title":"A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2011-02-01","conditions":"Infection, Human Immunodeficiency Virus I","enrollment":844},{"nctId":"NCT02509195","phase":"PHASE4","title":"SSAT064: Pharmacokinetics of Abacavir/Lamivudine/Dolutegravir in HIV Patients of 60 Years and Over","status":"COMPLETED","sponsor":"St Stephens Aids Trust","startDate":"2015-08-04","conditions":"HIV","enrollment":40},{"nctId":"NCT03256422","phase":"PHASE3","title":"Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients","status":"UNKNOWN","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2017-09-07","conditions":"HIV Infections","enrollment":640},{"nctId":"NCT00951015","phase":"PHASE2","title":"A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive Subjects","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2009-07-30","conditions":"Infection, Human Immunodeficiency Virus","enrollment":208},{"nctId":"NCT01449929","phase":"PHASE3","title":"Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2011-10-31","conditions":"Infection, Human Immunodeficiency Virus","enrollment":488},{"nctId":"NCT01928407","phase":"PHASE4","title":"Evaluation of the Efficacy and Safety Between Two Antiretroviral Regimens, in HIV-1-infected Treatment-naïve Subjects With Low CD4 Counts","status":"COMPLETED","sponsor":"Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba","startDate":"2011-02-23","conditions":"HIV-1 Infection, Immunosuppression-related Infectious Disease","enrollment":120},{"nctId":"NCT02246998","phase":"PHASE4","title":"Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naive HIV-1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-12-15","conditions":"HIV-1 Infection","enrollment":72},{"nctId":"NCT02556268","phase":"PHASE1","title":"Interaction With HIV Antiretroviral Agents","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-02-23","conditions":"HIV-DDI","enrollment":40},{"nctId":"NCT01448707","phase":"PHASE3","title":"A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2012-03-15","conditions":"Human Immunodeficiency Virus (HIV) Infections, Acquired Immunodeficiency Syndrome (AIDS) Virus","enrollment":274},{"nctId":"NCT01231555","phase":"PHASE2","title":"Dose-finding Study of GSK2248761 in Antiretroviral Therapy-Naive Subjects (SIGNET)","status":"TERMINATED","sponsor":"ViiV Healthcare","startDate":"2010-11-18","conditions":"Infection, Human Immunodeficiency Virus","enrollment":23},{"nctId":"NCT03275701","phase":"NA","title":"Evaluating BMD in Participants ≥50 Years Old Switching From EVG/COBI/FTC/TAF or EVG/COBI/FTC/TDF to ABC/DTG/3TC","status":"UNKNOWN","sponsor":"Mills Clinical Research","startDate":"2016-07","conditions":"Infection, Human Immunodeficiency Virus","enrollment":50},{"nctId":"NCT00433992","phase":"","title":"Metabolic Effects of Non-Thymidine Analogue Anti-HIV Medications","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-04","conditions":"HIV Infections","enrollment":56}],"_emaApprovals":[],"_faersSignals":[{"count":105,"reaction":"EXPOSURE DURING PREGNANCY"},{"count":92,"reaction":"FOETAL EXPOSURE DURING PREGNANCY"},{"count":88,"reaction":"PYREXIA"},{"count":83,"reaction":"RASH"},{"count":69,"reaction":"PAIN"},{"count":68,"reaction":"UPPER RESPIRATORY TRACT INFECTION"},{"count":67,"reaction":"VIROLOGIC FAILURE"},{"count":66,"reaction":"OFF LABEL USE"},{"count":65,"reaction":"THROMBOCYTOPENIA"},{"count":63,"reaction":"ASTHMA"}],"_approvalHistory":[{"date":"20131205","type":"ORIG","sponsor":"LUPIN LTD","applicationNumber":"ANDA202912"},{"date":"20201222","type":"SUPPL","sponsor":"LUPIN LTD","applicationNumber":"ANDA202912"},{"date":"20201222","type":"SUPPL","sponsor":"LUPIN LTD","applicationNumber":"ANDA202912"},{"date":"20220406","type":"SUPPL","sponsor":"LUPIN LTD","applicationNumber":"ANDA202912"},{"date":"20201222","type":"SUPPL","sponsor":"LUPIN LTD","applicationNumber":"ANDA202912"},{"date":"20201222","type":"SUPPL","sponsor":"LUPIN LTD","applicationNumber":"ANDA202912"}],"publicationCount":500,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Kivexa","Epzicom","ABC/3TC","ABC/3TC placebo","efavirenz"],"phase":"marketed","status":"active","brandName":"Abacavir/Lamivudine","genericName":"Abacavir/Lamivudine","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Abacavir and lamivudine are nucleoside reverse transcriptase inhibitors (NRTIs) that block HIV reverse transcriptase, preventing viral replication by inhibiting conversion of viral RNA to DNA. Used for HIV-1 infection (as part of combination antiretroviral therapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}